Congestive heart failure imposes a significant economic burden, highlighting the need for pharmacoeconomic analyses to guide cost-effective therapy.
Answers are grounded in this paper and cite their sources.
Heart failure's economic burden demands pharmacoeconomic evaluation now; leaves open optimal cost-effective therapies for future study.
The economic burden of congestive heart failure is significant. Approximately 1 to 2% of total health care expenditure is attributed to the diagnosis, treatment and prevention of congestive heart failure. A great share of this expenditure is related to the costs of long-term complications and productivity losses. In order to manage these costs, providers and policymakers increasingly have to focus on economically attractive interventions. Pharmacoeconomic analyses aid the systematic selection of cost-effective drug therapy in congestive heart failure in an era of increasing cost-containment.
No takes yet. Share an insight, caveat, or question.
Szucs et al. (2000) conducted a review in Congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: